Julia Appelskog

EU QPPV, Head of EU QPPV Office - Novavax

Dr. Appelskog is EU/UK QPPV and heading the QPPVs Office at Novavax. She an accomplished leader with over 20 years of experience leading all facets of PV and QA operations in healthcare sector, combined with 8 years of experience in cancer and diabetes research. Strategic thinker with proven capacity to implement effective PV strategies in adherence with industry best practices. Adept at biological, biopharmaceuticals products, including vaccines, OTC, generics, cosmetics, and medical devices.

In previous roles she was leading global teams at TFS (Head of QPPV and Safety Consulting), Bluefish Pharmaceuticals (Head of PV and EU QPPV), Merck (Head of PV Quality Management System and Policy as well as Head of PV Strategy). Julia was also responsible for Nordic PV Hubs at MSD, Johnson & Johnson and Sanofi Pasteur MSD.

Dr. Appelskog has accomplished a PhD Thesis in cell biology and diabetes at the Karolinska Institute (Sweden) in 2001, followed by a postdoctoral fellow position at the Department of Clinical Neuroscience at Karolinska Institute, conducting research on epigenetic mechanisms, modification of DNA and its associated proteins in tumor cells.

Julia was an active member of EMA EudraVigilance Working Group (EWPWG), EuropaBio, International PV Working Group (IPWG) at EFPIA, TransCelerate, AESGP, Medicine for Europe and the Chairman of PV Working Group at Swedish Generic Medicines Association (FGL)